Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Suresh S. Ramalingam; Chandra P. Belani; Christopher Ruel; Paul Frankel; Barbara J. Gitlitz

doi:10.1097/jto.0b013e318191520c

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Suresh S. Ramalingam, Chandra P. Belani, Christopher Ruel, Paul Frankel, Barbara J. Gitlitz, Marianna Koczywas, Igor Espinoza‐Delgado, David R. Gandara

Elsevier BV (2009) • Volume 4, Issue 1, Pages 97-101

PDF Available

Quick Actions

Read Full Paper

Publication Info

DOI

10.1097/jto.0b013e318191520c

Language

English

Topic

Peptidase Inhibition and Analysis

Keywords

Medicine, Mesothelioma, Internal medicine, Oncology, Regimen, Gastroenterology, Pathology

Published

January 1, 2009

Citations

157 citations

FWCI

8.81

External Resources

DOI Link OpenAlex

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

Quick Actions

Publication Info

External Resources

Suggested Papers

Therapeutic Efficacy of a Modified Ketogenic Diet in Autism Spectrum Disorder: A Randomized Controlled Trial

Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials

Differential rhythmicity: detecting altered rhythmicity in biological data

Suggested Papers

Suggested Papers

Therapeutic Efficacy of a Modified Ketogenic Diet in Autism Spectrum Disorder: A Randomized Controlled Trial

Third-generation versus first-generation EGFR tyrosine kinase inhibitors in Asian patients with advanced EGFR mutant non-small cell lung cancer: a meta-analysis of randomized controlled trials

Differential rhythmicity: detecting altered rhythmicity in biological data